Shanghai Labway Clinical Laboratory Co Ltd (301060) - Total Assets
Based on the latest financial reports, Shanghai Labway Clinical Laboratory Co Ltd (301060) holds total assets worth CN¥2.35 Billion CNY (≈ $343.64 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 301060 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Shanghai Labway Clinical Laboratory Co Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Shanghai Labway Clinical Laboratory Co Ltd's total assets have evolved over time, based on quarterly financial data. See 301060 book value for net asset value and shareholders' equity analysis.
Shanghai Labway Clinical Laboratory Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Labway Clinical Laboratory Co Ltd's total assets of CN¥2.35 Billion consist of 76.4% current assets and 23.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 33.1% |
| Accounts Receivable | CN¥682.91 Million | 29.8% |
| Inventory | CN¥269.81 Million | 11.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥23.67 Million | 1.0% |
| Goodwill | CN¥7.66 Million | 0.3% |
Asset Composition Trend (2013–2025)
This chart illustrates how Shanghai Labway Clinical Laboratory Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Shanghai Labway Clinical Laboratory Co L.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Labway Clinical Laboratory Co Ltd's current assets represent 76.4% of total assets in 2025, a decrease from 89.5% in 2013.
- Cash Position: Cash and equivalents constituted 33.1% of total assets in 2025, up from 15.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 29.8% of total assets.
Shanghai Labway Clinical Laboratory Co Ltd Competitors by Total Assets
Key competitors of Shanghai Labway Clinical Laboratory Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ICON Public Limited Company
F:IJF
|
Germany | €16.51 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Cytogen Inc
KQ:217330
|
Korea | ₩62.24 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
Shanghai Labway Clinical Laboratory Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.26 | 3.18 | 5.23 |
| Quick Ratio | 2.76 | 2.60 | 4.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.27 Billion | CN¥1.38 Billion | CN¥1.14 Billion |
Shanghai Labway Clinical Laboratory Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Labway Clinical Laboratory Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.76 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -12.6% |
| Total Assets | CN¥2.29 Billion |
| Market Capitalization | $515.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Labway Clinical Laboratory Co Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Labway Clinical Laboratory Co Ltd's assets decreased by 12.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Labway Clinical Laboratory Co Ltd (2013–2025)
The table below shows the annual total assets of Shanghai Labway Clinical Laboratory Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.29 Billion ≈ $335.42 Million |
-12.62% |
| 2024-12-31 | CN¥2.62 Billion ≈ $383.88 Million |
-12.17% |
| 2023-12-31 | CN¥2.99 Billion ≈ $437.07 Million |
-20.28% |
| 2022-12-31 | CN¥3.75 Billion ≈ $548.29 Million |
+77.96% |
| 2021-12-31 | CN¥2.11 Billion ≈ $308.10 Million |
+43.08% |
| 2020-12-31 | CN¥1.47 Billion ≈ $215.33 Million |
+5.18% |
| 2019-12-31 | CN¥1.40 Billion ≈ $204.72 Million |
-3.06% |
| 2018-12-31 | CN¥1.44 Billion ≈ $211.19 Million |
+8.51% |
| 2017-12-31 | CN¥1.33 Billion ≈ $194.63 Million |
+40.90% |
| 2016-12-31 | CN¥943.94 Million ≈ $138.13 Million |
+66.85% |
| 2015-12-31 | CN¥565.75 Million ≈ $82.79 Million |
+22.12% |
| 2014-12-31 | CN¥463.27 Million ≈ $67.79 Million |
+40.67% |
| 2013-12-31 | CN¥329.33 Million ≈ $48.19 Million |
-- |
About Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more